Cited 33 times in
Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김재훈 | - |
dc.date.accessioned | 2015-04-23T17:13:02Z | - |
dc.date.available | 2015-04-23T17:13:02Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/102044 | - |
dc.description.abstract | The human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine has been demonstrated to be highly efficacious and immunogenic with a favorable safety profile. This study assessed the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Korean girls aged 10-14 yr. This multi-center, observer-blind trial randomly assigned 321 healthy girls to receive three doses (0, 1, 6-month schedule) of HPV-16/18 AS04-adjuvanted vaccine or hepatitis A vaccine. Immunogenicity against vaccine antigens was assessed one month post-Dose 3. Solicited and unsolicited adverse events (AEs) and serious AEs (SAEs) were recorded. In the according-to-protocol analysis, all initially seronegative subjects vaccinated with the HPV-16/18 AS04-adjuvanted vaccine had seroconverted at Month 7, with a peak geometric mean titer (GMT) that was 600-fold higher than the natural infection titer of 29.8 EU/mL for HPV-16 and a peak GMT that was 400-fold higher than the natural infection titer of 22.6 EU/mL for HPV-18. The vaccine was well tolerated with no increase in reactogenicity with subsequent doses and no reports of vaccine-related SAEs. In conclusion, the HPV-16/18 AS04-adjuvanted vaccine is shown to be highly immunogenic and generally well-tolerated in Korean girls aged 10-14 yr | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1197~1204 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adjuvants, Immunologic/administration & dosage | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Aluminum Hydroxide/administration & dosage | - |
dc.subject.MESH | Antibodies, Viral/analysis | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatitis A/immunology | - |
dc.subject.MESH | Hepatitis A Vaccines/administration & dosage | - |
dc.subject.MESH | Hepatitis A Vaccines/adverse effects | - |
dc.subject.MESH | Hepatitis A Vaccines/immunology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lipid A/administration & dosage | - |
dc.subject.MESH | Lipid A/analogs & derivatives | - |
dc.subject.MESH | Papillomavirus Infections/prevention & control* | - |
dc.subject.MESH | Papillomavirus Vaccines/administration & dosage | - |
dc.subject.MESH | Papillomavirus Vaccines/adverse effects | - |
dc.subject.MESH | Papillomavirus Vaccines/immunology* | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Seroepidemiologic Studies | - |
dc.subject.MESH | Uterine Cervical Neoplasms/prevention & control* | - |
dc.title | Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics & Gynecology (산부인과학) | - |
dc.contributor.googleauthor | Young-Jae Kim | - |
dc.contributor.googleauthor | Kyung-Tai Kim | - |
dc.contributor.googleauthor | Jae-Hoon Kim | - |
dc.contributor.googleauthor | Soon-Do Cha | - |
dc.contributor.googleauthor | Jae Weon Kim | - |
dc.contributor.googleauthor | Duk-Soo Bae | - |
dc.contributor.googleauthor | Joo-Hyun Nam | - |
dc.contributor.googleauthor | Woong-Shick Ahn | - |
dc.contributor.googleauthor | Ho-Sun Choi | - |
dc.identifier.doi | 10.3346/jkms.2010.25.8.1197 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00876 | - |
dc.relation.journalcode | J01517 | - |
dc.identifier.eissn | 1598-6357 | - |
dc.identifier.pmid | 20676333 | - |
dc.subject.keyword | AS04-adjuvanted | - |
dc.subject.keyword | Adolescent | - |
dc.subject.keyword | HPV-16/18 | - |
dc.subject.keyword | Human papillomavirus | - |
dc.subject.keyword | Immunogenicity | - |
dc.subject.keyword | Prophylactic Vaccine | - |
dc.subject.keyword | Safety | - |
dc.subject.keyword | Uterine Cervical Neoplasms | - |
dc.subject.keyword | VLP | - |
dc.contributor.alternativeName | Kim, Jae Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Jae Hoon | - |
dc.citation.volume | 25 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1197 | - |
dc.citation.endPage | 1204 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.25(8) : 1197-1204, 2010 | - |
dc.identifier.rimsid | 52683 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.